Author

Rana Mckay

h-index 1 View on Semantic Scholar

We have 3 of 28 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

19 Dissecting ARNT Expression Patterns in RCC and Association with Outcomes

Abstract Background Hypoxia signaling is a key driver of renal cell carcinoma (RCC) and is mediated by HIF-dependent transcription. ARNT (HIF-1β) is an essential HIF binding partner, but its expression and clinical relevance in RCC are poorly defined. With ARNT inhibitors in development, characterizing ARNT expression...

Yu-Wei Chen, S. Nazari, A. Elliott et al. · The Oncologist · 0 citations

Open access Sep 2026

8 Single Cell Transcriptomic Investigation of Renal Cell Carcinoma (RCC) Reveals Tissue Resident Memory Exhausted CD8+ T Cell Signature Associated with Resistance to Immune Checkpoint Inhibition (ICI)

Abstract Background The current standard of care for advanced RCC is ICI-based combination therapies. However, most patients with advanced RCC develop disease progression despite ICI treatment, suggesting a lack of durable immune response. Although a lack of T cell infiltration or the presence of non-tumor-reactive “by...

Rishabh Rout, S. Kashima, M. Hugaboom et al. · The Oncologist · 0 citations

Open access Sep 2026

23 PRISM: Phase 1b of Retifanlimab and Ruxolitinib in Solid Malignancies Progressing on Prior Checkpoint Inhibition (NCT07219576)

Abstract Background Despite improved outcomes with programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immune checkpoint inhibitors (ICI) in renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC), most patients develop resistance. Preclinical data demonstrate that Janus kinase inhibition (...

Rana Mckay, L.-J. Wei, Yu-Wei Chen et al. · The Oncologist · 0 citations